Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital : a 30-year retrospective study by S. Grignolo et al.
Pregnancy and neonatal outcomes among a cohort of
HIV-infected women in a large Italian teaching hospital:
a 30-year retrospective study
S. GRIGNOLO1*†, R. AGNELLO2†, D. GERBALDO2, C. GOTTA3, C. ALICINO4,
F. DEL PUENTE1, L. TARAMASSO1, B. BRUZZONE5, C. GUSTAVINO2,
S. TRASINO3, A. DE MARIA1, G. ICARDI4, C. VISCOLI1 AND A. DI BIAGIO1‡
FOR GENOVA HIV NEONATAL AND PREGNANCY WORKING GROUP
1 Infectious Diseases Unit, IRCCS AOU San Martino-IST, University of Genoa, L.go Rosanna Benzi 10, 16132
Genoa, Italy
2Department of Obstetrics and Gynaecology, IRCCS AOU San Martino-IST, University of Genoa, L.go
Rosanna Benzi 10, 16132 Genoa, Italy
3Neonatal Unit, IRCCS AOU San Martino-IST, L.go Rosanna Benzi 10, 16132 Genoa, Italy
4Department of Health Sciences, University of Genoa, Via A. Pastore 1, 16132, Genoa, Italy
5Hygiene Unit, IRCCS AOU San Martino-IST, L.go Rosanna Benzi 10, 16132 Genoa, Italy
Received 6 September 2016; Final revision 14 February 2017; Accepted 22 February 2017;
ﬁrst published online 22 March 2017
SUMMARY
The primary study objective was to investigate three decades from 1985 to 2014 of changes in
pregnancies among HIV-infected women. The secondary objective was to assess risk factors
associated with preterm delivery and severe small-for-gestational-age (SGA) infants in HIV-
infected women. A retrospective review of deliveries among pregnant HIV-infected women at the
University of Genoa and IRCCS San Martino-IST in Genoa between 1985 and 2014 was
performed. Univariate and multivariable analyses were used to study the variables associated
with neonatal outcomes. Overall, 262 deliveries were included in the study. An increase in
median age (26 years in 1985–1994 vs. 34 years in 2005–2014), in the proportion of foreigners
(none in 1985–1994 vs. 27/70 (38·6%) in 2005–2014), and a decrease in intravenous drug use
(75·2% (91/121) in 1985–1994 vs. 12·9% (9/70) in 2005–2014) among pregnant HIV-infected
women was observed. Progressively, HIV infections were diagnosed sooner (prior to pregnancy in
80% (56/70) of women in the last decade). An increase in combined antiretroviral therapy
(cART) prescription during pregnancy (50% (27/54) in 1995–2004 vs. 92·2% (59/64) in 2005–
2014) and in HIV-RNA <50 copies/ml at delivery (19·2% (5/26) in 1995–2004 vs. 82·3% (53/64)
in 2005–2014) was observed. The rate of elective caesarean section from 1985 to 1994 was 9·1%,
which increased to 92·3% from 2004 to 2015. Twelve (10·1%) mother-to-child transmissions
(MTCT) occurred in the ﬁrst decade, and six (8·3%) cases occurred in the second decade, the last
of which was in 2000. Preterm delivery (<37 weeks gestation) was 5% (6/121) from 1985 to 1994
and increased to 17·1% (12/70) from 2005 to 2014. In univariate and multivariable logistic
regression analyses, advancing maternal age and previous pregnancies were associated with
preterm delivery (odds ratio (OR) 2·7; 95% conﬁdence intervals (CI) 1–7·8 and OR 2·6; 95% CI
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1·1–6·7, respectively). In the logistic regression analysis, use of heroin or methadone was found to
be the only risk factor for severe SGA (OR 3·1; 95% CI 1·4–6·8). In conclusion, signiﬁcant
changes in demographic, clinical and therapeutic characteristics of HIV-infected pregnant women
have occurred over the last 30 years. Since 2000, MTCT has decreased to zero. An increased risk
of preterm delivery was found to be associated with advancing maternal age and previous
pregnancies but not with cART. The use of heroin or methadone has been conﬁrmed as a risk
factor associated with severe SGA.
Key words: HIV, mother-to-child transmission, pregnancy, preterm delivery, small for gestational
age.
INTRODUCTION
Recommendations regarding the management of
HIV-infected women during pregnancy have evolved
considerably in Europe in recent years, reﬂecting
changes in the epidemic, as well as in the knowledge
of HIV prevention and treatment [1]. In the USA,
the overall annual rate of mother-to-child transmis-
sion (MTCT) of HIV decreased from 3% to 2%
from 2005 to 2008 [2]. In the UK and Ireland,
MTCT rates have continued to decline since 2006,
reaching an all-time low of 0·46% in 2010–2011 [3].
In Italy, between 2013 and 2014, only nine children
acquired an HIV infection during pregnancy, labour
or breastfeeding [4]. Nevertheless, debates about sev-
eral issues such as the overuse of elective caesarean
deliveries remain open, particularly regarding
women who have plasma HIV-RNA <50 copies/ml
and no other contraindication to a vaginal delivery
[5]. Current guidelines recommend a caesarean section
only when the mother has a detectable HIV-RNA [5],
since it can result in a potentially useless and harmful
intervention when the maternal viral load is undetect-
able [6]. Moreover, the incidence and frequency of
adverse pregnancy outcomes, in particular in women
receiving antiretroviral therapy (ART), might require
further investigation. Finally, recent changes in HIV
epidemiology and their potential inﬂuence on en-
gagement in care, therapy adherence and retention
in care are of particular interest, along with the
sociodemographic and lifestyle factors of these
patients [7]. In this context, the primary changes
recorded in Italy within the last years have been char-
acterised by an increase in the number of foreign citi-
zens diagnosed with HIV and a change in risk factors
for infection (i.e., an increase in heterosexual trans-
mission in women compared with the one caused by
intravenous drug use) [4]. Moreover, Italian women
are now the oldest in Europe at the time of their
ﬁrst pregnancy [8].
The primary objective of the study was to analyse
trends and patterns of pregnancies among HIV-
infected women over three decades in a ‘real-life’ set-
ting of care. A secondary objective was to assess the
risk factors associated with preterm delivery and
severe small-for-gestational-age (SGA) infants in
HIV-infected women. This observational, longitudinal
study includes the full database of deliveries among
HIV-infected women from 1985 to 2014 that occurred
at University of Genoa and IRCCS San Martino-IST
in Genoa, Italy.
METHODS
A retrospective review of deliveries among HIV-
infected women followed at the University of Genoa
and IRCCS San Martino-IST in Genoa between
January 1985 and December 2014 was performed.
The study population includes women from the
European Collaborative Study (ECS), a prospective
cohort study enrolling HIV-positive pregnant women
in 10 European countries in 1985–2011, and women
excluded from the ECS. Our research centre enrolled
HIV-positive women in ECS from 1985 to 2004.
Therefore, our cohort of HIV-infected pregnant
women was composed of women enrolled in the
ECS in 1985–2004, women excluded from the ECS
because they did not fulﬁl the eligibility criteria (preg-
nant women who received HIV diagnosis before or
during pregnancy) and women with pregnancy in
2005–2014. The informed consent of women enrolled
in ECS was obtained before their enrolment, whereas
informed consent of other women was not required, as
this is a clinical audit of routinely collected clinical
data. However, informed consent for the use of anon-
ymised data for scientiﬁc purposes was signed by all
patients admitted to IRCCS AOU San Martino –
IST and included in the study. A consent from the
Ethical Committee of Liguria Region was obtained
Pregnancy in HIV+ women over three decades 1659
https://doi.org/10.1017/S095026881700053X
Downloaded from https://www.cambridge.org/core. NATO Defence College, on 21 Feb 2020 at 11:08:50, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
for data analysis and publication purposes. According
to the ECS protocol [9], the collected data included
demographic characteristics, HIV infection, hepatitis
C virus (HCV) and hepatitis B virus (HBV) co-infection,
heroin and methadone use during pregnancy, plasma
HIV-RNA load at delivery, ART before and during
pregnancy, antiretroviral prophylaxis during labour
and delivery, and mode of delivery. Information on
preterm delivery, birth weight, mode of infant feeding
and HIV infection were also obtained for each new-
born. The analyses were based on the number of preg-
nancies rather than women, thus some women were
included more than once.
Years of delivery were grouped in three decades:
1985–1994, 1995–2004 and 2005–2014. The timing
of HIV diagnosis was classiﬁed as it occurred: (a)
prior to pregnancy, in women already known to be
HIV infected; (b) during pregnancy, in women
screened for HIV infection during pregnancy and
resulted HIV positive; (c) at/after delivery, in women
not screened for HIV during pregnancy but only at
or immediately after delivery. In term of exposure to
ART, pregnancies were classiﬁed as untreated, treated
with monotherapy or dual therapy, and receiving
combined antiretroviral therapy (cART). cART was
categorised as protease inhibitor (PI)-based regimen
or else, based on the PIs inclusion or exclusion.
CD4+ T-cell count (not routinely reported before
2000) was categorised as <200 cells/μl, 200–499 cells/
μl and 5500 cell/μl. The latest CD4+ T-cell count
before delivery was included in the analysis. HIV-1
RNA levels were determined through the following
assays: Nuclisens EasyQ HIV-1 2·0 (BioMérieux SA,
Marcy l’Etoile, France). Tests were usually carried
out on plasma samples, but occasionally on stored
serum samples. HIV-RNA (collected from 1998
onward) was categorised as undetectable (450 cop-
ies/ml) or detectable (>50 copies/ml), according to
the cut-off value deﬁning virological suppression
reported in European and Italian Guidelines [10,
11]. The closest to delivery HIV-RNA value was
used in the analysis.
Mode of delivery was reported as vaginal or per
caesarean section. Caesarean section was deﬁned as
elective when performed before the onset of labour
and with intact membranes, and as emergency in the
other cases. Delivery was deﬁned as preterm when it
occurred before the 37th week of gestation. A severe
SGA birth was identiﬁed with a newborn birth weight
lower than the 3rd percentile for the gestational age
[12]. A narrow deﬁnition of SGA was used because
infants with birth weight lower than 3rd percentile
were strongly and most consistently associated with
adverse perinatal outcome [13]. HIV status in the
infant was investigated as follows: at birth, at 2–4–6
weeks of age and at 3–6–9–12–18–24 months of age
(as the infant was still positive at 18 month) using
both serological and molecular assays. For the sero-
logical follow-up, Vironostika HIVAg/Ab UniForm
EIA (BioMérieux Laboratories, Boxtel, NL, USA),
Genscreen Plus HIV Ag/Ab EIA (Bio-rad, Marne la
Coquette, France) and New Lav Blot I (Bio-rad,
Marne la Coquette, France) were performed. For
the molecular follow-up, HIV-1 RNA and HIV-1
DNA in PBMC (peripheral blood mononuclear
cells) were performed. HIV-RNA was measured by
using Nuclisens EasyQ HIV-1 2·0 (BioMérieux SA,
Marcy l’Etoile, France). HIV-1 DNA was measured
by using the C-PCR (commercial PCR) system manu-
factured by Amplimedical S.p.A – Bioline Division
(Italy), designed to amplify a 600-base pair (bp)
undeﬁned pol region since the test was available on
the market; subsequently, HIV-1 DNA was performed
by using a H-PCR (homemade PCR) system designed
to amplify a highly conserved 508 bp HIV-1 pol inte-
grase region [14]. HIV infection was excluded if HIV
serological and molecular assays were negative.
Statistical analysis
All statistical analyses were performed using Epi-Info
7·0 (Centers for Disease Control and Prevention
(CDC), Atlanta, GA, USA) and JMP ® 10 (SAS
Institute Inc., Cary, NC, USA) software for Windows.
Continuous numeric variables were summarised as
mean and standard deviation for normalised distribu-
ted variables and as median and interquartile range
for non-normalised variables. Categorical variables
were summarised in the form of percentage
proportions.
The baseline characteristics of the study population
by decade of pregnancy were compared using χ2 and
Fisher exact test [15] and the differences in numeric
variables were evaluated through ANOVA (analysis
of variance) test for normalised distributed variables
or Wilcoxon signed-rank test for non-parametric stat-
istical analysis as appropriate [16].
For the assessment of factors associated with pre-
term birth and severe SGA, continuous variables
were dichotomised and cut-off values were determined
through ROC (receiver operating characteristic)
curves. Then, all variables were compared in
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univariate analyses by the χ2 test or the Fisher exact
test, as appropriate. These tests were performed for
both comparisons and they all were two-sided. To
assess the independent role of risk factors, variables
with a P value <0·05 in univariate comparisons were
included in logistic regression models. The odds
ratio (OR), 95% conﬁdence intervals (95% CI) and
corresponding P values obtained in the logistic regres-
sion models were reported.
All tests were two-tailed and a P value <0·05 was
determined to represent statistical signiﬁcance.
RESULTS
Our cohort included 262 deliveries from 231
HIV-infected women. One hundred and twenty-one
deliveries (46·2%) occurred in the decade 1985–1994,
71 deliveries (27·1%) occurred in the decade 1995–
2004 and 70 deliveries (26·7%) within the period
2005–2014. Of these deliveries, 143 (54·6%) were in
women enrolled in the ECS and 119 were in women
not enrolled in ECS because they were diagnosed
with HIV at or after their delivery (49, 18·7%) or
they became pregnant after 2004 (70, 26·7%). The
demographic and clinical characteristics of the
women, stratiﬁed by decade, are listed in Table 1.
Brieﬂy, in the ﬁrst decade all women were Italian,
their median age was 26 years, and drug injection
was the most frequent risk factor for HIV infection
(91/121, 75·2%). Twenty-four out of 121 patients
(19·8%) were HCV-infected, 50/121 women (41·3%)
were diagnosed prior to their pregnancy and 28/121
women (23·2%) were diagnosed during their preg-
nancy. In the last decade, 27/70 women (38·6%)
were not Italian, the median age was 34 years, 44/70
patients (62·9%) had heterosexual intercourse as a
risk category for HIV infection and 7/70 women
(10%) were HCV co-infected. The diagnosis of HIV
infection was performed prior to pregnancy in the
majority of cases (56/70, 80%). Conversely, among
the foreigners the median age was 31 years for
African women and 36 years for South-American
women, and the majority of them had heterosexual
intercourse as a risk category for HIV infection (21/
22, 91·5% of South-American women and 6/11,
54·5% of African women), and HCV co-infection
was uncommon (1/22, 4·5% among South-American
women and 0% among African women) (Supplemen-
tary Table S1 in the Supplementary Material). Almost
all of the differences in demographic and clinical char-
acteristics analysed according to calendar year and
ethnic group were statistically signiﬁcant based on
univariate analysis (P< 0·001, for all the characteris-
tics noted above). In the ﬁrst decade, all patients
were not on ART at conception and almost all (107/
121, 88·4%) had not been treated during pregnancy.
All 14 patients treated with ART in this period
received monotherapy. The proportion of patients
on ART at conception and during pregnancy was
signiﬁcantly higher in foreign women compared with
Caucasian women (19/22, 86·4% and 9/22, 40·9%
among South-American women and 9/11, 81·8% and
4/11, 36·4% among African women, respectively), and
increased during the following decades (9/71, 12·7%
and 36/71, 76·1% in the second decade, 36/70, 51·4%
and 64/70, 91·4% in the third decade, respectively,
P < 0·001), as well as the proportion of women
receiving cART (27/71, 50% in the second decade,
59/70, 92·2% in the third decade, P< 0·001).
Demographic and clinical characteristics of HIV-infected
pregnant women according to use of methadone or
heroin are listed in Supplementary Table S2 in
the Supplementary Material. Information related to
CD4+ T-cell count and plasma HIV-RNA load at
delivery was available only for a small number of
women (91/262, 35% and 90/262, 34%, respectively).
The proportion of women with HIV-RNA load
450 copies/ml at delivery was signiﬁcantly higher in
recent years (5/26, 19·2% in 1995–2004 vs. 53/64,
82·3% in 2005–2014, P < 0·001).
In the ﬁrst decade, vaginal delivery was the most
frequent mode of delivery (107/121, 88·4%), while
elective caesarean sections progressively increased in
the following years (11/121, 9·1% in 1985–1994; 44/
71, 63·7% in 1995–2004; 65/70, 92·9% in 2005–2014,
P < 0·001). In the last decade, no women delivered
vaginally, 65/70 (92·9%) women had an elective cae-
sarean section and 5/70 (7·1%) women had an emer-
gency caesarean section. Of the women who received
an elective caesarean section, 55/84 (65·5%) had an
undetectable plasma HIV-RNA load at delivery
(Supplementary Table S3 in the Supplementary
Material).
The number of twin pregnancies was one in the ﬁrst
decade, one in the second decade and two in the third
decade. The rate of preterm delivery was signiﬁcantly
higher in the last decade (6/121, 5·0% in 1985–1994;
7/71, 9·8% in 1995–2004; 12/70, 17·1% in 2005–2014,
P = 0·02). Severe SGAs were similar in the three peri-
ods (23/121, 19·5% in 1985–1994; 21/71, 29·6% in
1995–2004; 11/70, 15·7% in 2005–2014; P = 0·11).
Four infants were characterised by both preterm
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Table 1. Demographic and clinical characteristics of HIV-infected pregnant women and neonatal outcome according









P valuen/N (%) n/N (%) n/N (%) n/N (%)
Total deliveries 262 121 71 70
Median age (IQR) 28 (25–34) 26 (23–28) 31 (28–36) 34 (29–37) <0·001
Ethnic group <0·001
Caucasian 227/262 (86·6) 121/121 (100) 63/71 (88·7) 43/70 (61·4)
Not Caucasian 35/262 (13·4) 0/121 (0) 8/71 (11·3) 27/70 (38·6)
South-American 22/35 (62·9) – 6/8 (75) 16/27 (59·3)
African 11/35 (31·4) – 2/8 (25) 9/27 (33·3)
Asian 2/35 (5·7) – 0/8 (0) 2/27 (7·4)
HIV risk factors (mode of transmission)
Injecting drugs use 127/262 (48·5) 91/121 (75·2) 27/71 (38) 9/70 (12·9) <0·001
Heterosexual intercourse 99/262 (37·8) 22/121 (18·2) 33/71 (46·5) 44/70 (62·9) <0·001
MTCT 3/262 (1·1) 0/121 (0) 0/71 (0) 3/70 (4·3) 0·02
Other 33/262 (12·6) 8/121 (6·6) 11/71 (15·5) 14/70 (20) 0·02
Co-infection
HCV co-infection 60/262 (22·9) 24/121 (19·8) 29/71 (40·8) 7/70 (10) <0·001
HBV co-infection 32/262 (12·2) 18/121 (56·3) 11/71 (15·4) 3/70 (4·3) 0·06
HBV and HCV co-infection 16/262 (6·1) 5/121 (4·1) 9/71 (12·7) 2/70 (2·9) 0·02
Smoke 53/262 (20·2) 29/121 (24) 17/71 (24) 7/70 (10) 0·04
Methadone or heroin 39/262 (14·9) 25/121 (20·6) 11/71 (15·5) 3/70 (4·3) 0·009
Timing of HIV diagnosis <0·001
Prior to pregnancy 161/262 (61·5) 50/121 (41·3) 55/71 (77·5) 56/70 (80)
During pregnancy 48/262 (18·3) 28/121 (23·2) 10/71 (14·1) 10/70 (14·3)
At/after delivery 53/262 (20·2) 43/121 (35·5) 6/71 (8·4) 4/70 (5·7)
ART at conception 45/262 (17·2) 0/121 (0) 9/71 (12·7) 36/70 (51·4) <0·001
ART prescription during pregnancy 132/262 (50·4) 14/121 (11·6) 54/71 (76·1) 64/70 (91·4) <0·001
Monotherapy/dual therapy 46/132 (34·8) 14/14 (100) 27/54 (50) 5/70 (7·8) <0·001
cART 86/132 (65·2) 0/14 (0) 27/54 (50) 59/70 (92·2) 0·005
cART protease inhibitor based 67/86 (50·8) – 16/27 (29·6) 51/59 (79·7)
Mode of delivery (n= 260) <0·001
Vaginal 127/260 (48·8) 107/121 (88·4) 20/69 (29) 0/70 (0)
Elective caesarean section 120/260 (46·2) 11/121 (9·1) 44/69 (63·7) 65/70 (92·9)
Emergency caesarean section 13/260 (5) 3/121 (2·5) 5/69 (7·3) 5/70 (7·1)
Antiretroviral prophylaxis intrapartum 117/262 (44·7) 0/121 (0) 51/71 (71·8) 66/70 (94·3) <0·001
HIV-RNA load at delivery† (n= 90) <0·001
Undetectable (450 cp/ml) 58/90 (64·4) – 5/26 (19·2) 53/64 (82·8)
Detectable (>50 cp/ml) 32/90 (35·6) – 21/26 (80·8) 11/64 (17·2)
CD4+ T-cell at delivery† (n= 91) 0·005
<200 cell/mm3 3/91 (3·3) 1/5 (20) 1/26 (3·8) 1/60 (1·6)
200–499 cell/mm3 29/91 (31·9) 3/5 (60) 13/26 (50) 13/60 (21·7)
5500 cell/mm3 59/91 (64·8) 1/5 (20) 12/26 (46·2) 46/60 (76·7)
Previous pregnancy 93/262 (35·5) 30/121 (24·7) 29/71 (40·9) 34/70 (48·6) 0·002
Previous pregnancy interruption 99/262 (37·8) 54/121 (44·6) 27/71 (38) 18/70 (25·7) 0·03
Previous spontaneous abortion 29/262 (11·1) 14/121 (11·6) 7/71 (9·9) 8/70 (11·4) 0·92
PROM 95/262 (36·3) 73/121 (60·3) 17/71 (23·9) 5/70 (7·1) <0·001
Preterm delivery‡ 25/262 (9·5) 6/121 (5) 7/71 (9·8) 12/70 (17·1) 0·02
Severe SGA§ 55/262 (21) 23/121 (19·5) 21/71 (29·6) 11/70 (15·7) 0·11
Infant’s HIV infection (n= 263)¶ 18/263 (6·8) 12/119 (10·1) 6/72 (8·3) 0/72 (0) 0·02
IQR, interquartile range; MTCT, mother-to-child transmission; HBV, hepatitis B virus; HCV, hepatitis C virus; ART, anti-
retroviral therapy; cART, combined antiretroviral therapy; PROM, premature rupture of membranes; SGA, small for gesta-
tional age.
* Percentages exclude unknown/missing results.
†Measurement closest to delivery.
‡Delivery was deﬁned as preterm when it occurred before 37th gestational week.
§Severe SGA birth was deﬁned when newborn birth weight was lower than the 3rd percentile for the gestational age.
¶In the ﬁrst decade, there were three deaths in newborns after delivery and one twin pregnancy. One twin pregnancy was in the
second and two were in the third decade.
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delivery and severe SGA birth. Only three infants were
breastfed (2/121 in 1985–1994 and 1/71 in 1995–2004).
In the ﬁrst decade, three newborns died after delivery
and their serological status was unknown. Overall, 18
newborns (6·8%) were HIV-infected, all in the period
1985–2004. Of these newborns, 12 (10·1%) were
born in the ﬁrst decade and 6 (8·3%) were born in
the second decade. The last case of MTCT was
observed in 2000.
The results of the univariate analysis and multivari-
able logistic regression analysis for the preterm deliv-
eries are listed in Table 2. An advanced maternal age
(age 532 years) and previous pregnancies were the
maternal factors associated with preterm delivery
(OR 2·9; 95% CI 1·1–8·4; P = 0·03 and OR 2·5; 95%
CI 1–6·4; P < 0·05, respectively). The univariate and
multivariable logistic regression analyses for severe
SGA infants are reported in Table 3. Among the
maternal risk factors explored, only the maternal use
of heroin or methadone during pregnancy was corre-
lated with severe SGA infants (OR 3·1; 95% CI 1·4–
6·8; P = 0·007).
DISCUSSION
In this cohort of HIV-infected pregnant women from
a large teaching hospital in Genoa, we described the
changes in demographic, clinical and therapeutic
characteristics and neonatal outcomes that occurred
in the decades 1985–2014. In short, we report a sign-
iﬁcant increase in the median age (currently 34
years) and in the proportion of foreigners among
HIV-infected pregnant women (currently 38·6%).
Furthermore, in the last decade the most frequent
risk factor for HIV infection in pregnant women has
shifted away from injected drug use to heterosexual
intercourse, and vertical transmission has become
another risk category for HIV infection among preg-
nant women. With the reduction in injecting drug
use as a risk factor, the number of HCV co-infected
pregnant women decreased as well from 19·8% in
1985–1994 to 10% in 2005–2014, as observed among
the HIV-infected general population [17]. In recent
years, the proportion of patients on ART at concep-
tion and during pregnancy signiﬁcantly increased, as
expected. In fact, in the last decade 51·4% of women
were on ART at conception and 91·4% received treat-
ment during their pregnancy. Among antiretroviral
regimens, cART has become the most widely used
(92·2%), achieving the suppression of HIV-RNA
load at delivery in the majority of cases (82·8%).
These changes in the epidemiology of HIV-infected
pregnant women reported in our cohort are consistent
with surveillance data and ﬁndings of previously pub-
lished studies [17–21]. In a pooled analysis of data on
HIV-infected pregnant women enrolled in the Swiss
Mother & Child HIV Cohort Study and the ECS
between 2000 and 2010, Aebi-Popp et al. reported
data similar to ours: overall, 48% women were
black, the most common mode of HIV acquisition
was heterosexual contact (76%), 16% of women had
a history of injecting drug use, the majority of preg-
nant women were aware of their HIV diagnosis before
conception (72%), 91% received ART throughout
their pregnancy and delivery and 86% had an
undetectable HIV-RNA load at delivery [20]. In our
cohort, foreign women were older than Italian
women (median age, 31 years for African women,
36 years for South-American women vs. 28 years for
Italian women). Moreover, they were more likely to
be receiving ART at conception and a higher propor-
tion of them received cART during pregnancy com-
pared with Caucasian women. Even though the
fraction of foreigners has been increasing in the recent
years, overall they represented only 13·4% of the
women in our cohort.
The prevalence of elective caesarean sections pro-
gressively increased within the last few years to become
the most frequent mode of delivery (92·9% elective and
7·1% emergency caesarean sections). The very high
rate of elective caesarean section deliveries reported
in our study is not surprising considering that Italy is
the country with the highest rate of caesarean sections
among HIV-uninfected women in the European
Union [22]. We note, however, that this situation con-
tradicts European and national guidelines [10, 11, 23].
Elective caesarean sections have been recommended
to prevent MTCT in the absence of ART since 1997
[24, 25]. However, with the growing use of cART the
additional beneﬁt of an elective caesarean section in
reducing MTCT became uncertain; European and
national guidelines changed and now recommend
vaginal deliveries for all HIV-infected women with
an undetectable HIV-RNA load at delivery in the
absence of an obstetric indication for an elective cae-
sarean section. We reported ‘real-life’ data in which
the high rate of elective caesarean sections could
be partially justiﬁed and may have contributed to
reducing MTCT, considering that during the last
decade 5·7% of HIV diagnoses in our cohort still
occurred at/after delivery, only 91·4% of pregnant
women received cART during pregnancy and 17·2% of
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Univariate analysis Multivariable analysis*
OR (CI 95%) P value
Adjusted OR
(CI 95%) P valuen/N (%) n/N (%)
Decade of birth 0·02 0·82
1985–1994 115/237 (48·5) 6/25 (24) Reference Reference
1995–2004 64/237 (27) 7/25 (28) 2·1 (0·7–6·7) 0·8 (0·1–6·4)
2005–2014 58/237 (24·5) 12/25 (48) 4 (1·5–11·9) 1·2 (0·1–11·4)
Age 532 years 71/237 (30) 17/237 (66·7) 4·7 (2–12) <0·001 2·7 (1–7·8) <0·05
Ethnic group 0·83
Caucasian 205/237 (86·5) 22/237 (88) Reference
Not Caucasian 32/237 (13·5) 3/237 (12) 0·9 (0·2–2·7)
HIV risk factors (mode of transmission)
Injecting drugs use 114/237 (48·1) 13/25 (52) 1·2 (0·5–2·7) 0·71
Heterosexual intercourse 90/237 (38) 9/25 (36) 0·9 (0·4–2·1) 0·85
MTCT 3/237 (1·3) 0/25 (0) 2·3 (0–8·7) >0·99
Other 30/237 (12·7) 3/25 (12) 0·9 (0·2–2·9) 0·92
Co-infection
HCV co-infection 54/237 (22·8) 6/25 (24) 1·1 (0·4–2·7) 0·89
HBV co-infection 31/237 (13·1) 1/25 (4) 0·3 (0·01–1·4) 0·14
HBV and HCV co-infection 15/237 (6·3) 1/25 (4) 0·6 (0·03–3·3) 0·62
Smoke 49/237 (20·7) 4/25 (16) 0·7 (0·2–2) 0·57
Use of methadone or heroin 34/237 (14·4) 5/25 (20) 1·5 (0·5–4) 0·47
Timing of HIV diagnosis 0·05
Prior to pregnancy 143/237 (60·3) 18/25 (72) Reference
During pregnancy 42/237 (17·7) 6/25 (24) 1·1 (0·4–2·9)
At/after delivery 52/237 (21·9) 1/25 (4) 0·2 (0·01–0·8)
ART at conception 41/237 (17·3) 4/25 (16) 0·9 (0·3–2·5) 0·87
ART prescription during pregnancy 115/237 (48·5) 17/25 (68) 2·3 (1–5·7) 0·06
Type of ART during pregnancy 0·09 0·86
No ART 122/237 (51·5) 8/25 (32) Reference Reference
Monotherapy/dual therapy 42/237 (17·7) 4/25 (16) 1·5 (0·4–4·9) 0·7 (0·1–3·5)
cART 73/237 (30·8) 13/25 (52) 2·7 (1·1–7·2) 0·6 (0·1–3·4)
Antiretroviral prophylaxis intrapartum 99/237 (41·8) 18/25 (72) 3·6 (1·5–9·5) 0·004 2·8 (0·4–57·4) 0·32
HIV-RNA load at delivery‡ (n= 90) 0·54
Undetectable (450 cp/ml) 50/76 (65·8) 8/14 (57·1) Reference
Detectable (>50 cp/ml) 26/76 (34·2) 6/14 (42·9) 1·4 (0·4–4·6)
CD4+ T-cell at delivery‡ (n= 91) 0·61
<200 cell/mm3 3/78 (3·8) 0/13 (0) Reference
200–499 cell/mm3 25/78 (32·1) 4/13 (30·8) Not estimable
5500 cell/mm3 50/78 (64·1) 9/13 (69·2) Not estimable
Previous pregnancy 78/237 (32·9) 15/25 (60) 3·1 (1·3–7·3) 0·008 2·6 (1·1–6·7) 0·04
Previous pregnancy interruption 90/237 (38) 9/25 (36) 0·9 (0·4–2·1) 0·85
Previous spontaneous abortion 27/237 (11·4) 2/25 (8) 0·7 (0·1–2·5) 0·59
PROM 88/237 (37·1) 7/25 (28) 0·7 (0·2–1·6) 0·36
MTCT, mother-to-child transmission; HBV, hepatitis B virus; HCV, hepatitis C virus; ART, antiretroviral therapy; cART,
combined antiretroviral therapy; PROM, premature rupture of membranes.
*Variables with P< 0·1 in univariate analysis (decade of birth, age532 years, type of ART during pregnancy, antiretroviral
prophylaxis intrapartum and previous pregnancy) were included in multivariable analysis. Timing of HIV diagnosis and ART
prescription during pregnancy were excluded from multivariable analysis because of collinearity with the variable ‘type of
ART during pregnancy’.
† Percentages exclude unknown/missing results.
‡Measurement closest to delivery.
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Table 3. Univariate and multivariable logistic regression analysis for severe SGA infants (newborn birth weight lower





Univariate analysis Multivariable analysis*
OR (95% CI) P value
Adjusted OR
(95% CI) P valuen/N (%) n/N (%)
Decade of birth 0·11
1985–1994 98/207 (47·3) 23/55 (41·8) Reference
1995–2004 50/207 (24·2) 21/55 (38·2) 1·8 (1–5·2)
2005–2014 59/207 (28·5) 11/55 (20) 0·8 (0·4–1·7)
Age 532 years 67/207 (32·4) 21/55 (39·2) 1·3 (0·7–2·4) 0·41
Ethnic group 0·88
Caucasian 179/207 (86·5) 48/55 (87·3) Reference
Not Caucasian 28/207 (13·5) 7/55 (12·7) 0·9 (0·4–2·2)
HIV risk factors (mode of transmission)
Injecting drugs use 96/207 (46·4) 31/55 (56·4) 1·5 (0·8–2·7) 0·19
Heterosexual intercourse 84/207 (40·6) 15/55 (27·3) 0·6 (0·3–1·3) 0·07 0·8 (0·3–1·6) 0·48
MTCT 2/207 (1) 1/55 (1·8) 1·9 (0·1–20·2) 0·62
Other 25/207 (12·1) 8/55 (14·6) 1·2 (0·5–2·8) 0·63
Co-infection
HCV co-infection 43/207 (20·8) 17/55 (30·9) 1·7 (0·9–3·3) 0·12
HBV co-infection 25/207 (12·1) 7/55 (12·7) 1·1 (0·4–2·5) 0·9
HBV and HCV co-infection 12/207 (5·8) 4/55 (7·3) 1·3 (0·3–3·8) 0·69
Smoke 36/207 (17·4) 17/55 (30·9) 2·1 (1·1–4·1) 0·03 1·8 (0·8–3·7) 0·13
Use of methadone or heroin 22/207 (10·6) 17/55 (30·9) 3·8 (1·8–7·8) <0·001 3·1 (1·4–6·8) 0·007
Timing of HIV diagnosis 0·7
Prior to pregnancy 126/207 (60·9) 35/55 (63·6) Reference
During pregnancy 40/207 (19·3) 8/55 (14·6) 0·7 (0·3–1·6)
At/after delivery 41/207 (19·8) 12/55 (21·8) 1·1 (0·5–2·2)
ART at conception 40/207 (19·3) 5/55 (9·1) 0·4 (0·2–1) 0·06 0·4 (0·1–1·3) 0·16
ART prescription during pregnancy 106/207 (51·2) 26/55 (47·3) 0·9 (0·5–1·5) 0·6
Type of ART during pregnancy 0·8
No ART 101/207 (48·8) 29/55 (52·7) Reference
Monotherapy/dual therapy 36/207 (17·4) 10/55 (18·2) 1 (0·4–2·1)
cART 70/207 (33·8) 16/55 (29·1) 0·8 (0·4–1·6)
Antiretroviral prophylaxis intrapartum 92/207 (44·4) 25/55 (45·5) 1 (0·6–1·9) 0·89
HIV-RNA load at delivery‡ (n= 90) 0·51
Undetectable (450 cp/ml) 47/71 (66·2) 11/19 (57·9) Reference
Detectable (>50 cp/ml) 24/71 (33·8) 8/19 (42·1) 1·4 (0·5–4)
CD4+ T-cell at delivery‡ (n= 91) 0·46
<200 cell/mm3 2/72 (2·8) 1/19 (5·3) Reference
200–499 cell/mm3 11/72 (29·2) 8/19 (52·6) 0·8 (0·06–17·7)
5500 cell/mm3 49/72 (68·1) 10/19 (52·6) 0·41 (0·04–9·3)
Previous pregnancy 74/207 (35·8) 19/55 (34·6) 0·9 (0·5–1·8) 0·87
Previous pregnancy interruption 83/207 (40·1) 16/55 (29·1) 0·6 (0·3–1·2) 0·13
Previous spontaneous abortion 22/207 (10·6) 7/55 (12·7) 1·2 (0·5–2·9) 0·66
PROM 75/207 (36·2) 20/55 (36·4) 1 (0·5–1·9) 0·99
SGA, small for gestational age; MTCT, mother-to-child transmission; HBV, hepatitis B virus; HCV, hepatitis C virus; ART,
antiretroviral therapy; cART, combined antiretroviral therapy; PROM, premature rupture of membranes.
*Variables with P< 0·1 in univariate analysis (heterosexual intercourse as mode of transmission, smoke, use of methadone or
heroin, ART at conception) were included in multivariable analysis.
† Percentages exclude unknown/missing results.
‡Measurement closest to delivery.
Pregnancy in HIV+ women over three decades 1665
https://doi.org/10.1017/S095026881700053X
Downloaded from https://www.cambridge.org/core. NATO Defence College, on 21 Feb 2020 at 11:08:50, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
women were not virologically suppressed at delivery.
Nevertheless, in the last decade only 15/65 (23·1%)
of the caesarean sections occurred in women not
virologically suppressed or with a plasma HIV-RNA
load not known at delivery. This suggests that in
76·9% of cases the caesarean section was not justiﬁed
according to national and international guidelines.
The procedure might have instead been due to the
gynaecologists’ clinical concern regarding the the-
oretical risk of HIV transmission associated with
obstetrical interventions.
In our cohort, HIV vertical transmission rates
gradually decreased during the ﬁrst decade and then
rapidly dropped between 1995 and 2000. No instances
of MTCT occurred since 2000. This dramatic decrease
in MTCT is consistent with data published in other
European studies that reported a decrease in HIV ver-
tical transmission rates from 15% to 25% in the early
1990s to <2% in recent years [9, 26, 27]. In the UK
and Ireland, the rate of MTCT declined from 2·1%
in 2000–2001 to 0·46% in 2010–2011 due to the wide-
spread use of cART [3]. The zeroing of MTCT among
HIV-infected pregnant women in our cohort since
2000 is a remarkable achievement, enabled by excel-
lent improvements in HIV detection rates before or
at least during early pregnancy, the extensive and rou-
tine use of cART among HIV-infected women and the
use of elective caesarean sections in women not viro-
logically suppressed.
In our study, preterm delivery rose substantially
from 5·0% in the ﬁrst decade to 17·1% in recent
years. The increase in preterm deliveries since the
second decade may be related to ART, which has
been routinely prescribed in pregnancy since 1994
[28]. In our cohort, only 45 women conceived on
ART and 132 were on ART during pregnancy; 46
were receiving mono/dual therapy and 86 were receiv-
ing cART. Although the statistical power is low, our
multivariable regression analysis revealed that pre-
term delivery was associated with maternal age and
previous live births; no association with cART or
other variables was noted. Other studies have investi-
gated the association between preterm delivery and
cART and noted heterogeneous results. A possible
association between cART and prematurity was ini-
tially suggested in 1998 in a Swiss study that reported
premature deliveries in 10 out of 30 women receiving
cART [29]. Townsend et al. reported that cART was
associated with a 1·5-fold increased risk of premature
delivery compared with mono/dual therapy [30].
Cotter et al. reported a similar association, but limited
to PI-containing regimens [31]. In contrast, Kourtis
et al., in their meta-analysis, did not demonstrate an
increased overall risk of premature delivery associated
with the use of cART, even though the early initiation
of cART during pregnancy appeared to confer a
slightly increased risk of premature delivery [32].
Finally, the just-published PROMISE trial reported
that preterm delivery was more frequent with
zidovudine-based ART than with zidovudine mono-
therapy [33]. Discrepant results among different stud-
ies could derive from differences in population
characteristics, the antiretroviral regimens used and
the study periods. The ECS reported an association
with the period of the study and increasing maternal
age [34]. Although our ﬁndings derived from a single
centre, they might concur to disprove the association
between preterm delivery and cART. The increase in
preterm delivery rates reported in recent years in our
study may be related to advancing maternal age rather
than cART use, considering that advanced maternal
age is a known risk factor for preterm delivery in
the general population [35]. Moreover, we found a
previous live birth to be risk factor for preterm deliv-
ery, in accordance with the ﬁndings of an observa-
tional Italian study conducted by Liuzzi et al. [19].
The mechanisms underlying preterm delivery are com-
plex and not completely understood. Nevertheless, an
investigation of these mechanisms is beyond the objec-
tives of this study.
The rate of severe SGA remained stable over the
course of the study period. In our study, severe SGA
was associated with the use of heroin or methadone,
but not with other risk factors. Although cART has
been suggested to be a possible risk factor for SGA,
the relation between SGA and cART remains unclear.
An increased risk of very low birthweight (<1500 g)
has been reported in one study [36], but not in others
[27, 31, 36]. Townsend et al. reported that
cART-exposed infants were of lower birthweight
than those exposed to mono/dual therapy, but the dif-
ference was not clinically signiﬁcant [30]. Other than
these studies, the association between SGA and
chronic use of methadone during pregnancy stems
from consolidated data [37–40]. The low statistical
power of our study was unable to yield solid evidence
for the absence of an association between preterm
delivery or SGA and cART.
The strength of our study is represented by its long
study period, which allowed us to describe the radical
demographic and clinical changes occurring in HIV-
infected pregnant women over the course of three
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decades. There were, however, a number of limitations
to our study. First, the small number of patients in our
cohort, which resulted in a low statistical power of our
analysis, represents the major limitation. Second, we
report a single-centre experience that included either
women enrolled prospectively from ECS and women
not enrolled in ECS or excluded women because of
their presentation at delivery. Third, due to the retro-
spective design of the study, limited obstetrical data
were available. Furthermore, immunological and viro-
logical data were available only for the last two dec-
ades and not for all patients. Finally, we included
only women whose pregnancies ended in birth; we
were accordingly unable to estimate changes in the
miscarriage rate.
In conclusion, our study highlights the changing
nature of the HIV-infected pregnant population.
Above all, the increase in the median age of
HIV-infected pregnant women could have an impact
on neonatal outcomes, such as an increased risk of
preterm delivery. The widespread use of cART prior
to and during pregnancy made it possible to achieve
the suppression of HIV-RNA load upon delivery in
the majority of cases, with a meaningful contribution
to the absolute decrease in MTCT. Nevertheless, in a
‘real-life’ setting of care there are still women showing
up late in their pregnancies and with detectable
HIV-RNA load at delivery. This situation persists
not only among foreigners but primarily among
Italian women. This fact suggests that it is important
to encourage clinicians to engage in early HIV testing
for all pregnant women and promote the routine use
of cART during pregnancy to maintain a high level
of clinical care for all women, who are pregnant or
are planning a pregnancy. Not delivering vaginally
represents a missed opportunity for HIV-infected
women on cART with a suppressed HIV-RNA load
and, according to international guidelines, caesarean
sections should be restricted to women with late
linkage-to-care and without virological suppression.
In this regard, future research is necessary to address
how earlier engagement in care among HIV-positive
pregnant women can be promoted, to achieve viral
suppression and the opportunity for HIV-positive
pregnant women to deliver vaginally.
Finally, the retrospective nature of our investigation
did not allow us to conﬁrm previous studies pertaining
to the missing association between cART and the
increased risk of preterm delivery or severe SGA.
With the changing nature of the HIV-infected female
population and the introduction of new antiretroviral
drugs as integrase strand transfer inhibitors, further
research is needed – especially randomised, controlled
clinical trials such as the PROMISE study [33] – to
assess the risk of preterm delivery and SGA in differ-
ent ethnic populations and in women receiving new
antiretroviral regimens.
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